Dr Michail Charakidis has proposed a new clinical trial to be conducted at Royal Darwin Hospital, Alan Walker Cancer Care Centre. This trial is part of the National Mutual Acceptance Scheme.

The purpose of this study is to compare the efficacy of targeted therapies or immunotherapy on patients who have solid tumours with specific genetic alterations or with a high number of mutations. Patients will be assigned to cohorts based on having specific type of genetic alteration or having a high number of mutations in their tumour.

The research is being sponsored globally by F. Hoffmann-La Roche Ltd, of Basel, Switzerland, and conducted locally in Australia by Roche Products Pty Limited.